×
About 74 results

ALLMedicine™ Synovial Cell Sarcoma Center

Research & Reviews  37 results

Nonrhabdomyosarcoma Soft Tissue Sarcomas
https://emedicine.medscape.com/article/991351-overview

Jan 27th, 2020 - Background Soft tissue sarcomas, the fifth most common solid tumors in children, are relatively rare and account for about 6-7% of all childhood malignancies. About half of these tumors are rhabdomyosarcomas, and nonrhabdomyosarcoma soft tissue sa...

Nonrhabdomyosarcoma Soft Tissue Sarcomas 
https://emedicine.medscape.com/article/991351-print

Jan 27th, 2020 - Background Soft tissue sarcomas, the fifth most common solid tumors in children, are relatively rare and account for about 6-7% of all childhood malignancies. About half of these tumors are rhabdomyosarcomas, and nonrhabdomyosarcoma soft tissue sa...

Cancer targeting by TCR gene-engineered T cells directed against Kita-Kyushu Lung Cance...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6712783
Journal for Immunotherapy of Cancer; Marcinkowski B, Stevanović S et. al.

Aug 28th, 2019 - T cell receptor (TCR) gene-engineered T cells have shown promise in the treatment of melanoma and synovial cell sarcoma, but their application to epithelial cancers has been limited. The identification of novel therapeutic TCRs for the targeting o...

NY-ESO-1-specific T Cell Receptor (TCR) T Cell in Sarcoma
https://clinicaltrials.gov/ct2/show/NCT03462316

Sep 13th, 2018 - This is a one arm, open label, dose escalation, single dose phase I study. The investigators include first-line treatment failed advanced patients with bone or soft tissue sarcoma and without standard regimen;TCR-T cell therapy has made a breakthr...

To Evaluate the Efficacy of NY-ESO-1-specific T Cell Receptor (TCR) Affinity Enhancing Specific T Cell in Solid Tumors
https://clinicaltrials.gov/ct2/show/NCT03159585

Jan 16th, 2018 - TCR-T cell therapy has made a breakthrough for tumors in recent years. Phase I/II trial of NY-ESO-1-specific TCR-T treatment for synovial sarcoma and melanoma, conducted by the Rosenberg team at the National Cancer Institute, showed that 61% Synov...

see more →

Clinicaltrials.gov  37 results

Nonrhabdomyosarcoma Soft Tissue Sarcomas
https://emedicine.medscape.com/article/991351-overview

Jan 27th, 2020 - Background Soft tissue sarcomas, the fifth most common solid tumors in children, are relatively rare and account for about 6-7% of all childhood malignancies. About half of these tumors are rhabdomyosarcomas, and nonrhabdomyosarcoma soft tissue sa...

Nonrhabdomyosarcoma Soft Tissue Sarcomas 
https://emedicine.medscape.com/article/991351-print

Jan 27th, 2020 - Background Soft tissue sarcomas, the fifth most common solid tumors in children, are relatively rare and account for about 6-7% of all childhood malignancies. About half of these tumors are rhabdomyosarcomas, and nonrhabdomyosarcoma soft tissue sa...

Cancer targeting by TCR gene-engineered T cells directed against Kita-Kyushu Lung Cance...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6712783
Journal for Immunotherapy of Cancer; Marcinkowski B, Stevanović S et. al.

Aug 28th, 2019 - T cell receptor (TCR) gene-engineered T cells have shown promise in the treatment of melanoma and synovial cell sarcoma, but their application to epithelial cancers has been limited. The identification of novel therapeutic TCRs for the targeting o...

NY-ESO-1-specific T Cell Receptor (TCR) T Cell in Sarcoma
https://clinicaltrials.gov/ct2/show/NCT03462316

Sep 13th, 2018 - This is a one arm, open label, dose escalation, single dose phase I study. The investigators include first-line treatment failed advanced patients with bone or soft tissue sarcoma and without standard regimen;TCR-T cell therapy has made a breakthr...

To Evaluate the Efficacy of NY-ESO-1-specific T Cell Receptor (TCR) Affinity Enhancing Specific T Cell in Solid Tumors
https://clinicaltrials.gov/ct2/show/NCT03159585

Jan 16th, 2018 - TCR-T cell therapy has made a breakthrough for tumors in recent years. Phase I/II trial of NY-ESO-1-specific TCR-T treatment for synovial sarcoma and melanoma, conducted by the Rosenberg team at the National Cancer Institute, showed that 61% Synov...

see more →